Disparities in Huntington Disease Severity: Analysis Using the ENROLL-HD Dataset.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
07
04
2023
accepted:
06
09
2023
pmc-release:
01
12
2024
medline:
5
10
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
Social and structural determinants of health (SDOH) have been associated with disability in neurologic diseases. However, the association between these factors and disability in Huntington disease (HD) has not been studied. This study aimed to evaluate the association of racial and sociodemographic factors with disease severity in patients with HD in North America. We conducted a cross-sectional study of genetically confirmed participants with HD (36+ CAG repeats) in the North American region using the ENROLL-HD 2020 periodic dataset. In this analysis, our exposure variable was the participant's race/ethnicity. The main outcome measure was disease severity, as measured by the Total Functional Capacity Score (TFC), which measures the level of disability of patients with HD. We used multivariate regression models to adjust for sociodemographic factors that may mediate or moderate a causal effect between race/ethnicity and disease severity. Among 4,717 gene-positive participants in the North American region, 89.5% identified as White, 3.4% as Hispanic or Latino, and 2.3% as African American/Black. The average TFC score was 10.22 (SD 3.22); 48% of participants completed either secondary education (including college) or a professional degree, and 55% lived in a city and not in a town, village, or rural location. In multivariate regression models, we found that Black participants and those with less than a high school degree entered the ENROLL-HD study with lower TFC scores than White participants. We also found that compared with those with at least a high school degree, those who completed some form of higher education or professional degree had higher TFC scores ( Our study found that Black participants in North America presented to ENROLL-HD with more advanced disease than White patients. We also found that higher education was associated with less advanced disease when entering the ENROLL-HD study. The role of race/ethnicity and education in HD symptom severity warrants further investigation. These findings underscore the importance of further studying the role of social and structural determinants of health in patients with HD, particularly those from historically marginalized communities.
Sections du résumé
Background and Objectives
UNASSIGNED
Social and structural determinants of health (SDOH) have been associated with disability in neurologic diseases. However, the association between these factors and disability in Huntington disease (HD) has not been studied. This study aimed to evaluate the association of racial and sociodemographic factors with disease severity in patients with HD in North America.
Methods
UNASSIGNED
We conducted a cross-sectional study of genetically confirmed participants with HD (36+ CAG repeats) in the North American region using the ENROLL-HD 2020 periodic dataset. In this analysis, our exposure variable was the participant's race/ethnicity. The main outcome measure was disease severity, as measured by the Total Functional Capacity Score (TFC), which measures the level of disability of patients with HD. We used multivariate regression models to adjust for sociodemographic factors that may mediate or moderate a causal effect between race/ethnicity and disease severity.
Results
UNASSIGNED
Among 4,717 gene-positive participants in the North American region, 89.5% identified as White, 3.4% as Hispanic or Latino, and 2.3% as African American/Black. The average TFC score was 10.22 (SD 3.22); 48% of participants completed either secondary education (including college) or a professional degree, and 55% lived in a city and not in a town, village, or rural location. In multivariate regression models, we found that Black participants and those with less than a high school degree entered the ENROLL-HD study with lower TFC scores than White participants. We also found that compared with those with at least a high school degree, those who completed some form of higher education or professional degree had higher TFC scores (
Discussion
UNASSIGNED
Our study found that Black participants in North America presented to ENROLL-HD with more advanced disease than White patients. We also found that higher education was associated with less advanced disease when entering the ENROLL-HD study. The role of race/ethnicity and education in HD symptom severity warrants further investigation. These findings underscore the importance of further studying the role of social and structural determinants of health in patients with HD, particularly those from historically marginalized communities.
Identifiants
pubmed: 37795504
doi: 10.1212/CPJ.0000000000200200
pii: CPJ-2023-000177
pmc: PMC10547468
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e200200Informations de copyright
© 2023 American Academy of Neurology.
Déclaration de conflit d'intérêts
A. Mendizabal receives grant support from the Huntington's Disease Society of America (HDSA). A. Singh, S. Perlman, A. Brown, and Y. Bordelon report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Références
Ann Neurol. 2009 Aug;66(2):142-5
pubmed: 19743462
Mov Disord Clin Pract. 2017 Sep 11;4(5):682-688
pubmed: 30363491
Stroke. 2021 Aug;52(8):2562-2570
pubmed: 34078107
Mov Disord. 2021 Mar;36(3):757-761
pubmed: 33108688
Mov Disord Clin Pract. 2018 May 09;5(4):361-372
pubmed: 30363510
Neurology. 2022 Jun 14;98(24):1015-1020
pubmed: 35470139
Neurology. 2017 Jun 13;88(24):2268-2275
pubmed: 28515272
J Huntingtons Dis. 2015;4(4):347-69
pubmed: 26756591
J Am Heart Assoc. 2017 Sep 21;6(9):
pubmed: 28935679
Cureus. 2021 Mar 4;13(3):e13702
pubmed: 33728226
Am J Public Health. 2005 Nov;95(11):2065-70
pubmed: 16254235
Lancet Neurol. 2022 Jul;21(7):632-644
pubmed: 35716693
Int J Equity Health. 2021 Apr 7;20(1):96
pubmed: 33827600
Neurology. 2021 Feb 9;96(6):e840-e844
pubmed: 33372030
Mov Disord. 1996 Mar;11(2):136-42
pubmed: 8684382
MMWR Surveill Summ. 2016 Aug 05;65(8):1-12
pubmed: 27490513
Mov Disord. 2019 Jun;34(6):858-865
pubmed: 30868663
Arch Neurol. 2011 Apr;68(4):498-503
pubmed: 21149802
Mov Disord Clin Pract. 2016 Jun 22;4(2):212-224
pubmed: 30363395
Neuropsychiatr Dis Treat. 2019 Feb 22;15:603-609
pubmed: 30863081
Neurology. 2021 May 11;96(19):e2395-e2406
pubmed: 33766994
Cancer. 2008 Jan 15;112(2):228-42
pubmed: 18008363
J Health Care Poor Underserved. 2010 Aug;21(3):879-97
pubmed: 20693733
Psychiatry Res. 2010 Jul 30;178(2):414-8
pubmed: 20471695
PLoS Med. 2006 Feb;3(2):e19
pubmed: 16318411
Cephalalgia. 2018 Apr;38(5):876-882
pubmed: 28649860
J Neuropsychiatry Clin Neurosci. 2020 Spring;32(2):109-124
pubmed: 31466515
Mov Disord Clin Pract. 2019 Aug 23;6(7):541-546
pubmed: 31538087
Brain Sci. 2022 Jan 26;12(2):
pubmed: 35203927
Neurology. 1979 Jan;29(1):1-3
pubmed: 154626
Mov Disord Clin Pract. 2021 Mar 30;8(4):555-562
pubmed: 33981788
Am J Public Health. 2014 Feb;104(2):e16-31
pubmed: 24328648
Alzheimers Dement. 2022 Aug;18(8):1461-1471
pubmed: 34854531